MA38365A1 - Pyrimidines annelées à subsitution trifluorométhyle et utilisation correspondante - Google Patents

Pyrimidines annelées à subsitution trifluorométhyle et utilisation correspondante

Info

Publication number
MA38365A1
MA38365A1 MA38365A MA38365A MA38365A1 MA 38365 A1 MA38365 A1 MA 38365A1 MA 38365 A MA38365 A MA 38365A MA 38365 A MA38365 A MA 38365A MA 38365 A1 MA38365 A1 MA 38365A1
Authority
MA
Morocco
Prior art keywords
pyrimidines
ringed
corresponding use
prophylaxis
treatment
Prior art date
Application number
MA38365A
Other languages
English (en)
Inventor
Frank Wunder
Gorden Redlich
Markus Follmann
Dieter Lang
Alexandros Vakalopoulos
Adrian Tersteegen
Johannes-Peter Stasch
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47826961&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38365(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA38365A1 publication Critical patent/MA38365A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne de nouvelles pyrimidines annelées à substitution trifluorométhyle, leur procédé de fabrication, leur utilisation seules ou dans des combinaisons pour le traitement et/ou la prophylaxie de maladies, ainsi que leur utilisation pour fabriquer des médicaments destinés au traitement et/ou à la prophylaxie de maladies, notamment au traitement et/ou à la prophylaxie de maladies cardiovasculaires.
MA38365A 2013-03-01 2014-02-25 Pyrimidines annelées à subsitution trifluorométhyle et utilisation correspondante MA38365A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13157434 2013-03-01
PCT/EP2014/053636 WO2014131760A1 (fr) 2013-03-01 2014-02-25 Pyrimidines annelées à subsitution trifluorométhyle et utilisation correspondante

Publications (1)

Publication Number Publication Date
MA38365A1 true MA38365A1 (fr) 2017-09-29

Family

ID=47826961

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38365A MA38365A1 (fr) 2013-03-01 2014-02-25 Pyrimidines annelées à subsitution trifluorométhyle et utilisation correspondante

Country Status (28)

Country Link
US (1) US9266871B2 (fr)
EP (1) EP2961755B1 (fr)
JP (1) JP2016510010A (fr)
KR (1) KR20150121007A (fr)
CN (1) CN105308055B (fr)
AP (1) AP2015008637A0 (fr)
AR (1) AR094943A1 (fr)
AU (1) AU2014222739A1 (fr)
BR (1) BR112015020298A2 (fr)
CA (1) CA2902993A1 (fr)
CL (1) CL2015002343A1 (fr)
CR (1) CR20150448A (fr)
CU (1) CU20150095A7 (fr)
DO (1) DOP2015000185A (fr)
EA (1) EA027689B1 (fr)
HK (1) HK1220974A1 (fr)
IL (1) IL240637A0 (fr)
MA (1) MA38365A1 (fr)
MX (1) MX2015010966A (fr)
NI (1) NI201500117A (fr)
PE (1) PE20151755A1 (fr)
PH (1) PH12015501703A1 (fr)
SG (1) SG11201505974VA (fr)
TN (1) TN2015000370A1 (fr)
TW (1) TW201443066A (fr)
UY (1) UY35350A (fr)
WO (1) WO2014131760A1 (fr)
ZA (1) ZA201505911B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3415515B1 (fr) 2009-11-27 2019-12-25 Adverio Pharma GmbH Procédé de production de méthyl{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo [3,4-b]pyridin-3-yl]pyrimidin-5-yl}méthylcarbamate
EA201390060A1 (ru) 2010-07-09 2013-07-30 Байер Интеллектуэль Проперти Гмбх Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
DE102012200349A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung
DE102012200360A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte Triazine und ihre Verwendung
WO2013131923A1 (fr) 2012-03-06 2013-09-12 Bayer Intellectual Property Gmbh Azabicyles substitués et leur utilisation
EA201600096A1 (ru) 2013-07-10 2016-10-31 Байер Фарма Акциенгезельшафт Бензил-1н-пиразол[3,4-b]пиридины и их применение
WO2015106268A1 (fr) 2014-01-13 2015-07-16 Ironwood Pharmaceuticals, Inc. Utilisation de stimulateurs de la sgc pour le traitement de troubles neuromusculaires
AU2016258847A1 (en) 2015-05-06 2017-11-16 Bayer Pharma Aktiengesellschaft The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of Digital Ulcers (DU) concomitant to Systemic Sclerosis (SSc)
DK3325013T4 (da) 2015-07-23 2023-10-16 Bayer Pharma AG Stimulatorer og/eller aktivatorer af den opløselige guanylatcyklase (sgc) i kombination med en inhibitor af den neutrale endopeptidase (nep inhibitor) og en angiotensin aii-antagonist og deres anvendelse
EA201891416A1 (ru) 2015-12-14 2018-12-28 Айронвуд Фармасьютикалз, Инк. ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ ДИСФУНКЦИИ ЖЕЛУДОЧНО-КИШЕЧНОГО СФИНКТЕРА
WO2017121692A1 (fr) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft Sulfamides substitués et leur utilisation
WO2017121700A1 (fr) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft Dérivés de 1h-pyrazolo[3,4-b]pyridine 1,3-disubstitués et leur utilisation en tant que stimulateurs de la guanylacte cyclase soluble
JP7237823B2 (ja) 2016-10-11 2023-03-13 バイエル ファーマ アクチエンゲゼルシャフト Ｓｇｃアクチベーターとミネラルコルチコイド受容体アンタゴニストとを含む組合せ
US10918639B2 (en) 2016-10-11 2021-02-16 Bayer Pharma Aktiengesellschaft Combination containing SGC stimulators and mineralocorticoid receptor antagonists
EP3554488A2 (fr) 2016-12-13 2019-10-23 Cyclerion Therapeutics, Inc. Utilisation de stimulateurs de sgc pour le traitement de la motilité sophagienne
WO2018153899A1 (fr) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Agonistes partiels sélectifs du récepteur a1 de l'adénosine en combinaison avec des stimulateurs et/ou activateurs de la guanylate cyclase soluble (sgc)
US11242335B2 (en) 2017-04-11 2022-02-08 Sunshine Lake Pharma Co., Ltd. Fluorine-substituted indazole compounds and uses thereof
WO2019081353A1 (fr) * 2017-10-24 2019-05-02 Bayer Aktiengesellschaft Imidazopyridinamides substituées et leur utilisation
BR112020022340A2 (pt) 2018-05-15 2021-02-02 Bayer Aktiengesellschaft benzamidas substituídas por 1,3-tiazol-2-il para o tratamento de doenças associadas com sensibilização de fibras nervosas
EP3574905A1 (fr) 2018-05-30 2019-12-04 Adverio Pharma GmbH Procédé d'identification d'un sous-groupe de patients souffrant de dcssc qui bénéficie d'un traitement comportant des stimulateurs sgc et des activateurs sgc à un degré supérieur à celui d'un groupe de contrôle
AU2019301683A1 (en) 2018-07-11 2021-02-11 Tisento Therapeutics Inc. Use of sGC stimulators for the treatment of mitochonrial disorders
WO2020164008A1 (fr) 2019-02-13 2020-08-20 Bayer Aktiengesellschaft Procédé de préparation de microparticules poreuses
WO2020216669A1 (fr) 2019-04-23 2020-10-29 Bayer Aktiengesellschaft Imidazopyridinamides substitués par un phényle et leur utilisation
EP3822265A1 (fr) 2019-11-15 2021-05-19 Bayer AG Hydantoïnamides substitués comme antagonistes d'adamts7
EP3822268A1 (fr) 2019-11-15 2021-05-19 Bayer Aktiengesellschaft Hydantoinamides substitués comme antagonistes d'adamts7

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9314412D0 (en) 1993-07-13 1993-08-25 Rhone Poulenc Agriculture New compositions of matter
EP0743066A3 (fr) 1995-05-16 1998-09-30 Mitsui Pharmaceuticals, Inc. Agent cicatrisant
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
US6451805B1 (en) 1997-11-14 2002-09-17 Bayer Aktiengesellschaft Substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE10021069A1 (de) 2000-04-28 2001-10-31 Bayer Ag Substituiertes Pyrazolderivat
MXPA03003612A (es) 2000-10-23 2003-06-19 Smithkline Beecham Corp Compuestos novedosos.
ES2231581T3 (es) 2000-11-22 2005-05-16 Bayer Healthcare Ag Nuevos derivados de pirazolopiridina sustituidos con lactama.
DE10132416A1 (de) 2001-07-04 2003-01-16 Bayer Ag Neue Morpholin-überbrückte Pyrazolopyridinderivate
SE0102716D0 (sv) * 2001-08-14 2001-08-14 Astrazeneca Ab Novel compounds
DE10220570A1 (de) * 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE10232571A1 (de) 2002-07-18 2004-02-05 Bayer Ag 4-Aminosubstituierte Pyrimidinderivate
EP1626045B1 (fr) 2003-05-09 2010-09-08 Asahi Glass Company, Limited Methodes de production de 2-chloro-5-fluoropyridine 3-substitue ou de son sel
CN100355732C (zh) 2003-11-03 2007-12-19 上海药明康德新药开发有限公司 2－氯－5－氟－烟酸酯及酸的制备方法
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
DE102007027799A1 (de) * 2007-06-16 2008-12-18 Bayer Healthcare Ag Substituierte Furopyrimidine und ihre Verwendung
CA2694499A1 (fr) 2007-07-31 2009-02-05 Vertex Pharmaceuticals Incorporated Procede de preparation de la 5-fluoro-1h-pyrazolo[3,4-b]pyridin-3-amine et des derives de celle-ci
EP2373317B1 (fr) 2008-11-25 2016-12-14 Merck Sharp & Dohme Corp. Dérivés de 4-amino-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one ou 4-amino-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one en tant qu'activateurs de la cyclase du guanylat soluble pour le traitement de maladies cardio-vasculaires
WO2011115804A1 (fr) 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Stimulateurs de sgc
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EA023254B1 (ru) 2010-05-27 2016-05-31 Мерк Шарп Энд Домэ Корп. Активаторы растворимой гуанилатциклазы
WO2011161099A1 (fr) 2010-06-25 2011-12-29 Bayer Pharma Aktiengesellschaft Utilisation de stimulateurs et d'activateurs de la guanylate-cyclase soluble pour le traitement de la drépanocytose et la conservation de substituts sanguins
EP2590987B1 (fr) 2010-07-09 2016-03-09 Bayer Intellectual Property GmbH Dérivés de 4-aminopyrimidine condensées et leur utilisation en tant que stimulateurs de la guanylate cyclase soluble
EA201390060A1 (ru) 2010-07-09 2013-07-30 Байер Интеллектуэль Проперти Гмбх Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043380A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Benzyl-substituierte Carbamate und ihre Verwendung
US9090610B2 (en) 2011-04-21 2015-07-28 Bayer Intellectual Property Gmbh Fluoroalkyl-substituted pyrazolopyridines and use thereof
JP5976788B2 (ja) 2011-05-06 2016-08-24 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾピリジンおよびイミダゾピリダジンならびにそれらの使用
AU2012280246A1 (en) 2011-07-06 2014-01-23 Bayer Intellectual Property Gmbh Heteroaryl-substituted pyrazolopyridines and use thereof as soluble guanylate cyclase stimulators
BR112014004569A2 (pt) 2011-09-01 2017-06-13 F. Hoffmann-La Roche Ag composto da fórmula i, métodos para tratar condição inflamatória, artrite reumatoide, asma e distúrbio imune, composição farmacêutica e uso do composto
MX348470B (es) 2011-09-02 2017-06-13 Bayer Ip Gmbh Pirimidinas anilladas sustituidas y uso de las mismas.
DE102012200349A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung
DE102012200352A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung
DE102012200360A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte Triazine und ihre Verwendung
WO2013131923A1 (fr) 2012-03-06 2013-09-12 Bayer Intellectual Property Gmbh Azabicyles substitués et leur utilisation

Also Published As

Publication number Publication date
WO2014131760A1 (fr) 2014-09-04
NI201500117A (es) 2016-02-15
UY35350A (es) 2014-09-30
JP2016510010A (ja) 2016-04-04
CR20150448A (es) 2016-01-11
EP2961755B1 (fr) 2017-10-18
BR112015020298A2 (pt) 2017-07-18
AR094943A1 (es) 2015-09-09
MX2015010966A (es) 2016-04-04
SG11201505974VA (en) 2015-09-29
DOP2015000185A (es) 2015-11-15
TN2015000370A1 (en) 2017-01-03
CN105308055A (zh) 2016-02-03
AU2014222739A1 (en) 2015-09-03
CL2015002343A1 (es) 2016-08-12
KR20150121007A (ko) 2015-10-28
IL240637A0 (en) 2015-09-24
HK1220974A1 (zh) 2017-05-19
EA201591616A1 (ru) 2016-04-29
EP2961755A1 (fr) 2016-01-06
US9266871B2 (en) 2016-02-23
CU20150095A7 (es) 2016-02-29
CA2902993A1 (fr) 2014-09-04
PH12015501703A1 (en) 2015-10-12
PE20151755A1 (es) 2015-12-04
EA027689B1 (ru) 2017-08-31
AP2015008637A0 (en) 2015-08-31
CN105308055B (zh) 2017-07-14
ZA201505911B (en) 2016-10-26
TW201443066A (zh) 2014-11-16
US20140249168A1 (en) 2014-09-04

Similar Documents

Publication Publication Date Title
MA38365A1 (fr) Pyrimidines annelées à subsitution trifluorométhyle et utilisation correspondante
MA35365B1 (fr) Pyrimidines annelées substituées et leur utilisation
MA35844B1 (fr) Pyrimidines et triazines annelées substituées et leur utilisation
MA34248B1 (fr) 5-fluoro-1h-pyrazolopyridines substituées et leur utilisation
MA42376A (fr) Dérivés d'oxopyridine substitués
MA39934A (fr) Variants d'anticorps anti-facteur d et leurs utilisations
TN2014000470A1 (en) Bicyclically substituted uracils and the use thereof
MA38060A1 (fr) Imidazo[1,2-a]pyridincarboxamides amino-substitués et leur utilisation
PA8784001A1 (es) Oxazolidinonas sustituidas y su uso
MA38925A1 (fr) Dérivés de phénylalanine substitués
PH12017502224A1 (en) Positive allosteric modulators of muscarinic md receptor
MA46235B1 (fr) 1-aryl-naphtyridin-3-ylcarboxamides substitués en position 7 et leur utilisation
MA37928A1 (fr) Tri(hétéro)arylpyrazoles et leur utilisation
MA38637A1 (fr) Benzoxazoles substitués
MA38775A1 (fr) Benzyl-1h-pyrazolo[3,4-b]pyridine et utilisation de cette dernière
MA39118B1 (fr) Quinazoline-thf-amines utilisées en tant qu'inhibiteurs de la pde1
MA38950A1 (fr) Thiénouracile-carboxamides cycliques et utilisation associée
UA113887C2 (xx) 5-амінотетрагідрохінолін-2-карбонові кислоти і їх застосування